Document is current
Any future updates will be listed below
-
Authors
Stringer-Reasor, Erica M.
May, Jori E.
Olariu, Eva
Caterinicchia, Valerie
Li, Yufeng
Chen, Dongquan
Della Manna, Deborah L.
Rocque, Gabrielle B.
Vaklavas, Christos
Falkson, Carla I.
Nabell, Lisle M.
Acosta, Edward P.
Forero-Torres, Andres
Yang, Eddy S. http://orcid.org/0000-0002-6450-2638
-
Funding
Funding for this research was provided by:
AACR-TNBC Foundation Grant (15-20-43)
Scariot Foundation (NA)
- License Information
-
More Information
Article History
Received: 18 August 2020
Accepted: 18 February 2021
First Online: 4 March 2021
Ethics approval and consent to participate
: The study was reviewed and approved by the UAB Institutional Review Board.
: The manuscript contains images of an individual. Consent was obtained and available upon request.
: E. Yang: consultant for AstraZeneca; advisory board for Clovis Oncology, Strata Oncology, Bayer, and Lilly; research funding from Tesaro/Janssen.E. Stringer-Reasor: involved in clinical trials with money paid directly to UAB from Seattle Genetics, Pfizer, Novartis, TESARO, and GSK; on advisory boards for Mylan Institutional and Lilly; grants provided by Susan G. Komen and Victory Foundation.C. Falkson: advisory boards for Agendia, Biotheranostics, and Oncotype Dx.G. Rocque: grants from Genetech, Pfizer, and Carevive; consult for Pfizer.C. Vaklavas: consulting/advisory role: Daiichi-Sankyo (one time); research funding paid to my institution: Seattle Genetics, Genentech, Roche, Pfizer, Incyte, Pharmacyclics, Novartis, TRACON Pharmaceuticals, Innocrin Pharmaceuticals, Zymeworks, and H3 Biomedicine; other relationships: Puma Biotechnology, Takeda, Daiichi Sankyo; uncompensated relationship: Genentech (unpaid thought leader).E. Acosta, L, Yufeng, L. Nabell, J. May, E. Olariu, D. Della Manna, and V. Caterinicchia have no conflicts to disclose.
